PURPOSE: The overall published experience with pediatric type 1 Gaucher disease (GD1) has been based on ascertainment through clinical presentation of the disease. We describe the longitudinal follow-up in a presymptomatic pediatric cohort. METHODS: The cohort includes children diagnosed with GD1, either prenatally or postnatally by molecular genetic testing, and followed for clinical care at our center from 1998 to 2016. All patients' parents were GBA mutation carriers identified through carrier screening programs. Longitudinal clinical, laboratory, and imaging data were obtained through chart review. RESULTS: Thirty-eight patients aged 1-18 years (mean at last visit 6.9 ± 4.1 years) were followed, including 32 p.N409S homozygotes and 6 p.N409S/p.R535H compound heterozygotes. At the last evaluation, a minority had hematological (5%), bone (15%), or linear growth (19%) issues. Only 12% had splenomegaly and 74% had moderate hepatomegaly. Chitotriosidase activity varied widely (6-5,640 nmol/hour/ml) and generally increased with age. Pediatric Gaucher severity scores (GSS) remained stable and within the mild-disease range for most (95%). Treatment for progressive disease during this period was recommended for four children. CONCLUSION: Most children with the p.N409S/p.N409S and p.N409S/p.R535H GD1 genotypes have minimal disease manifestations and progression during childhood and can be monitored using limited assessments. Those with other mutations may require additional monitoring. These data are valuable for newborn screening and counseling.Genet Med advance online publication 13 October 2016.
PURPOSE: The overall published experience with pediatric type 1 Gaucher disease (GD1) has been based on ascertainment through clinical presentation of the disease. We describe the longitudinal follow-up in a presymptomatic pediatric cohort. METHODS: The cohort includes children diagnosed with GD1, either prenatally or postnatally by molecular genetic testing, and followed for clinical care at our center from 1998 to 2016. All patients' parents were GBA mutation carriers identified through carrier screening programs. Longitudinal clinical, laboratory, and imaging data were obtained through chart review. RESULTS: Thirty-eight patients aged 1-18 years (mean at last visit 6.9 ± 4.1 years) were followed, including 32 p.N409S homozygotes and 6 p.N409S/p.R535H compound heterozygotes. At the last evaluation, a minority had hematological (5%), bone (15%), or linear growth (19%) issues. Only 12% had splenomegaly and 74% had moderate hepatomegaly. Chitotriosidase activity varied widely (6-5,640 nmol/hour/ml) and generally increased with age. Pediatric Gaucher severity scores (GSS) remained stable and within the mild-disease range for most (95%). Treatment for progressive disease during this period was recommended for four children. CONCLUSION: Most children with the p.N409S/p.N409S and p.N409S/p.R535H GD1 genotypes have minimal disease manifestations and progression during childhood and can be monitored using limited assessments. Those with other mutations may require additional monitoring. These data are valuable for newborn screening and counseling.Genet Med advance online publication 13 October 2016.
Authors: Tamar H Taddei; Katherine A Kacena; Mei Yang; Ruhua Yang; Advitya Malhotra; Michael Boxer; Kirk A Aleck; Gadi Rennert; Gregory M Pastores; Pramod K Mistry Journal: Am J Hematol Date: 2009-04 Impact factor: 10.047
Authors: M Maas; T Hangartner; G Mariani; K McHugh; S Moore; G A Grabowski; P Kaplan; A Vellodi; J Yee; L Steinbach Journal: Skeletal Radiol Date: 2008-03 Impact factor: 2.199
Authors: Andrew J Degnan; Victor M Ho-Fung; Rebecca C Ahrens-Nicklas; Christian A Barrera; Suraj D Serai; Dah-Jyuu Wang; Can Ficicioglu Journal: Insights Imaging Date: 2019-07-10
Authors: Tama Dinur; Ari Zimran; Michal Becker-Cohen; David Arkadir; Claudia Cozma; Marina Hovakimyan; Sebastian Oppermann; Laura Demuth; Arndt Rolfs; Shoshana Revel-Vilk Journal: J Clin Med Date: 2019-10-11 Impact factor: 4.241